Business Context and Reporting Period
Company: Vanda Pharmaceuticals Inc. (VNDA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Vanda is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. Its commercial portfolio includes Fanapt (schizophrenia/bipolar I), HETLIOZ (Non-24/SMS), PONVORY (multiple sclerosis), and NEREUS (motion sickness). The company operates in a single reportable segment.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $216.1 | $198.8 | +9% |
| Net Loss | $(220.5) | $(18.9) | Worsened significantly |
| Operating Loss | $(151.2) | $(40.7) | Worsened |
| Cash & Cash Equivalents | $84.9 | $102.3 | -17% |
| Total Cash, Equivalents & Marketable Securities | $263.8 | $374.6 | -30% |
| Net Cash Used in Operating Activities | $(109.4) | $(15.8) | Increased outflow |
Revenue Breakdown (2025):
- Fanapt: $117.3 million (+24% vs 2024)
- HETLIOZ: $71.4 million (-7% vs 2024)
- PONVORY: $27.4 million (-2% vs 2024)
- NEREUS: $0 (Approved Dec 2025, commercial launch pending)
Expense Highlights:
- R&D Expenses: $109.3 million (+47% vs 2024), driven by the imsidolimab license acquisition and development programs.
- SG&A Expenses: $238.0 million (+63% vs 2024), driven by commercial launches of Fanapt (bipolar) and PONVORY.
- Income Tax Provision: $81.8 million (vs benefit of $4.0M in 2024), primarily due to a $113.7 million non-cash valuation allowance against deferred tax assets.
Material Changes vs. Prior Period
- Net Loss Expansion: The net loss widened from $18.9 million in 2024 to $220.5 million in 2025. This was primarily driven by a $113.7 million non-cash income tax expense (valuation allowance) and increased operating expenses.
- Revenue Growth: Total revenue grew 9% to $216.1 million. Fanapt sales grew 24% due to volume increases from the bipolar I disorder launch. HETLIOZ sales declined 7% due to generic competition and inventory dynamics.
- Strategic Acquisitions: The company incurred significant R&D costs related to the exclusive global license for imsidolimab (AnaptysBio), including a $10.0 million upfront payment and $5.0 million for drug supply.
- Regulatory Milestones: NEREUS received FDA approval for motion sickness in December 2025. The imsidolimab BLA was submitted for generalized pustular psoriasis.
Guidance, Outlook, Risks, and Contingencies
Outlook & Guidance:
- Management believes current cash resources ($263.8 million) are sufficient for at least the next 12 months.
- Key upcoming catalysts include the PDUFA date for Bysanti (Feb 21, 2026) and the commercial launch of NEREUS for motion sickness.
- No specific financial guidance for 2026 was provided in the text.
Material Risks & Contingencies:
- Generic Competition: HETLIOZ faces significant generic competition in the U.S. (Teva, Apotex, MSN) following adverse patent litigation rulings in 2022/2023. Sales volatility is expected to continue.
- Regulatory Disputes: The company is engaged in ongoing litigation with the FDA regarding HETLIOZ (jet lag/insomnia) and NEREUS (gastroparesis). In Jan 2026, the FDA determined the HETLIOZ jet lag sNDA could not be approved in its current form; hearing proceedings were requested.
- Patent Litigation: Pending trials against Teva and Apotex regarding HETLIOZ patents are scheduled for August 2026. A trial against MSN regarding HETLIOZ LQ is scheduled for September 2026.
- Reimbursement: The company faces challenges with third-party payors refusing coverage for HETLIOZ and pricing pressures from the Inflation Reduction Act (IRA).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $263.8 million cash position against the projected burn rate, given the significant increase in operating expenses and the lack of profitability.
- HETLIOZ Sales Trajectory: Monitor quarterly HETLIOZ sales for continued erosion due to generic competition and the impact of ongoing patent litigation outcomes scheduled for 2026.
- Valuation Allowance: Assess the likelihood of reversing the $113.7 million deferred tax valuation allowance, which requires sustained future taxable income.
- Regulatory Resolutions: Track the status of the FDA hearing proceedings for HETLIOZ (jet lag) and the NEREUS gastroparesis NDA, as these represent significant binary risks.
- NEREUS Commercialization: Evaluate the timeline and cost structure for the commercial launch of NEREUS for motion sickness and the initiation of Phase III trials for GLP-1 induced vomiting.